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Osteogenesis imperfecta — also known as brittle bone 
disease — is a phenotypically and genetically hetero­
geneous group of inherited bone dysplasias1. Although 
the primary clinical manifestation involves the skeleton, 
osteogenesis imperfecta is a generalized connective 
 tissue disorder. Individuals with osteo genesis imper­
fecta have low bone mass and bone fragility, resulting in 
susceptibil ity to fractures of the long bones and verte­
bral compressions, variable deformity of long bones, ribs 
and spine, and substantial growth deficiency. An array 
of associated secondary features can be present, includ­
ing blue sclerae, conductive or sensory hearing loss, 
dentino genesis imperfecta, malocclusion, basilar 
invagin ation (that is, a developmental deformity that 
causes narrowing of the foramen magnum (the open­
ing of the skull where the spinal cord passes through 
to the brain)), scoliosis, pulmonary function impair­
ment, cardiac valve abnormalities, muscle weakness and 
 ligamentous laxity2 (FIG. 1).
Osteogenesis imperfecta had been known since the 
early 1980s as a dominantly inherited disease caused by 
mutations in either of the genes encoding type I colla­
gen (that is, COL1A1 and COL1A2), the main compo­
nent of the extracellular matrix of bone and skin1. Since 
2006, new mutations in collagen­related genes — with 
different inheritance patterns — have been found to 
cause osteogenesis imperfecta3 (TABLE 1). Identification of 
these new causative genes has led to the adaptation 
of the original classification system for osteo genesis 
imperfecta (BOX 1; TABLE 1): the Sillence classifica­
tion. In this Primer, we use the genetic classification 
outlined in TABLE 1 whenever referring to the type of 
osteogenesis imperfecta.
The causative mutation is identified in most patients, 
which provides a basis for genetic counselling. Under­
standing the genetic defects also increases the pros­
pects for targeted therapies. In addition, most of the 
newly identified mutated genes encode proteins 
involved in pathways that were not previously known 
to be crucial for bone development. For example, prolyl 
 3­hydroxylation, the connected pathway between bone 
mineralization and vascular development, and regu­
lated intramembrane proteolysis, which has been exten­
sively studied for its effect on cholesterol metabolism, 
also affects bone4. As osteogenesis imperfecta has long 
served as a genetic model for severe osteopenia or osteo­
porosis, these discoveries have opened up new areas 
of bone research and enhanced interest in identify ing 
the causative genes in the few remaining patients with 
unknown mutations.
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Abstract | Skeletal deformity and bone fragility are the hallmarks of the brittle bone dysplasia 
osteogenesis imperfecta. The diagnosis of osteogenesis imperfecta usually depends on family history 
and clinical presentation characterized by a fracture (or fractures) during the prenatal period, at birth 
or in early childhood; genetic tests can confirm diagnosis. Osteogenesis imperfecta is caused by 
dominant autosomal mutations in the type I collagen coding genes (COL1A1 and COL1A2) in about 
85% of individuals, affecting collagen quantity or structure. In the past decade, (mostly) recessive, 
dominant and X‑linked defects in a wide variety of genes encoding proteins involved in type I collagen 
synthesis, processing, secretion and post-translational modification, as well as in proteins that 
regulate the differentiation and activity of bone-forming cells have been shown to cause osteogenesis 
imperfecta. The large number of causative genes has complicated the classic classification of the 
disease, and although a new genetic classification system is widely used, it is still debated. 
Phenotypic manifestations in many organs, in addition to bone, are reported, such as abnormalities 
in the cardiovascular and pulmonary systems, skin fragility, muscle weakness, hearing loss and 
dentinogenesis imperfecta. Management involves surgical and medical treatment of skeletal 
abnormalities, and treatment of other complications. More innovative approaches based on gene 
and cell therapy, and signalling pathway alterations, are under investigation.
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In this Primer, we provide an overview of epidemio­
logy, genetics and pathophysiology of osteogenesis 
imperfecta, as well as diagnosis and management.
Epidemiology
Studies from Europe and the United States have found a 
birth prevalence of osteogenesis imperfecta of 0.3–0.7 per 
10,000 births5,6. These birth cohort analyses reflect 
more­severe types of osteogenesis imperfecta and do not 
include more­subtle types that become apparent after 
birth. A population­based study that used the Danish 
National Patient Register found an annual incidence of 
osteogenesis imperfecta of 1.5 per 10,000 births between 
1997 and 2013 (REF. 7). Population surveys in countries 
with comprehensive medical databases, such as Finland, 
estimated a prevalence of about 0.5 per 10,000 individ­
uals8, with most having phenotypically milder osteo­
genesis imperfecta type I and type IV (BOX 1; TABLE 1). 
Because these birth cohort and population surveys 
are based on clinical findings and tend to find mutu­
ally exclusive populations, a reasonable estimate of the 
incidence of osteogenesis imperfecta is about 1 per 
10,000 individuals. Most patients are heterozygous for 
mutations in COL1A1 or COL1A2. No difference in the 
 prevalence between sexes was reported.
Approximately 90% of the 3,000 individuals whose 
mutations have been included in the osteogenesis imper­
fecta variant database (http://www.le.ac.uk/ge/ collagen/) 
have alterations in either COL1A1 or COL1A2, and 
the others have homozygous or biallelic mutations in 
one of the newly identified genes (TABLE 1). However, 
major sequencing centres offering a panel of causative 
mutations associated with osteogenesis imperfecta are 
identify ing a lower frequency of structural COL1A1 and 
COL1A2 mutations in patients with moderate­to­severe 
disease. For example, of 598 individuals at the Shriners 
Hospital in Montréal, Canada, in whom mutations were 
identified, 77% had heterozygous alterations in COL1A1 
or COL1A2, 9% had a single mutation in IFITM5 (osteo­
genesis imperfecta type V), and the remaining 12% had 
homozygous or biallelic mutations in other genes caus­
ing osteogenesis imperfecta9. Lethal collagen mutations 
may be under­represented in this population.
In populations with a high level of consanguinity or 
a high number of carriers, the incidence of osteogenesis 
imperfecta is higher than in outbred populations10–12. 
Among African Americans in the United States, for 
example, the carrier frequency for a single deleterious 
variant in P3H1 (previously named LEPRE1; encoding 
prolyl 3­hydroxylase 1) is about 1 in 240 individuals11. 
Homozygosity for this so­called West African allele 
accounts for 25% of all infants with lethal osteogenesis 
imperfecta in this population and might be clinically 
misclassified as osteogenesis imperfecta type II. By con­
trast, among West Africans in Ghana and Nigeria, the 
carrier frequency for this allele is 1.5% and would result 
in an incidence of lethal recessive osteogenesis imper­
fecta equal to the incidence of de novo mutations in 
type I collagen11. Among First Nations people in north­
ern Ontario, Canada, a single deep intronic vari ant 
results in the use of a cryptic exon that destabilizes the 
CRTAP (which encodes cartilage­associated protein) 
mRNA, and is responsible for the recessive osteogenesis 
imperfecta type VII10,13. As is the case for many recessive 
disorders, some populations harbour a single allele that 
accounts for the majority of individuals with a particular 
phenotype: a single exon deletion in TMEM38B found 
in individuals from Saudi Arabia14; a single frameshift in 
FKBP10 found in individuals from Turkey15; and a mis­
sense mutation in WNT1 in the Hmong people from 
Vietnam and China16.
Mechanisms/pathophysiology
Defects in type I collagen
Collagen synthesis and processing. Type I collagen — the 
major protein component of the extracellular matrix in 
bone, skin and tendon — is mainly secreted by osteo­
blasts, dermal fibroblasts and tenocytes (FIG. 2). Despite 
the relatively simple structure of the collagen triple helix, 
the biosynthesis of type I procollagen is extremely com­
plex, involving multiple steps and requiring an ensemble 
of proteins for post­ translational modifications, folding, 
transport, secretion and quality control17,18 (FIG. 3). The 
COL1A1 and COL1A2 transcripts are translated in the 
rough endoplasmic reticulum (rER), and the α(I)­chains 
undergo a series of post­translational modifications. 
Helical prolines in position Y of the Gly­Xaa­Yaa 
repeat (FIG. 2) are hydroxylated in position C4 by prolyl 
 4­hydroxylase 1 (P4H1), whereas speci fic prolines in the 
X positions are 3­hydroxylated by P3H1 and P3H2. Some 
lysine residues are hydroxylated by lysyl hydroxylases 
(LH1 and LH2), and glycosyl ation of hydroxylysines 
into galactosyl­hydroxylysine and glucosyl­ galactosyl­
hydroxylysine is catalysed by procollagen galacto­
syltrans fer ase 1 and procollagen glucosyltransferase 1 
(FIG. 3a). After synthesis of the carboxy­ terminal pro­
peptide, it forms intra­chain disulfide bonds and remains 
attached to the rER membrane (FIG. 3b). Selection and 
association of the   correct chains into a triple helix 
occur by diffusion of the C­propeptides attached to the 
rER  membrane. A nucleus for triple helix formation 
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is formed that staggers the chains in the correct order 
and initiates triple helix formation. Protein disulfide 
isomerase cataly ses inter­chain disulfide bond forma­
tion, which stabil ize the folding nucleus. Hydroxylation 
of proline residues and some lysine residues continues 
and  triple helix formation proceeds from the C­terminal 
end towards the amino­terminal end. During this phase, 
65 kDa FK506­binding protein (FKBP65; encoded by 
FKBP10) and a complex formed by P3H1 — CRTAP–
PPIase B (peptidyl­prolyl cis–trans isomerase B) — seem 
to play a crucial part. The complex is involved in the 
hydroxyl ation of proline 986 of the collagen α1(I)­chain 
and α1(II)­chain and proline 707 of the α2(I)­chain13,19–21, 
which are thought to be important for supramolecular 
assembly of collagen fibrils and to serve as binding sites 
for chaperones or small leucine­rich proteoglycans22. 
Beyond its prolyl 3­hydroxylase activity, the com­
plex functions as a PPIase and chaperone for collagen 
folding13,19,23. Indeed, the fast propagation of the triple 
helix requires the isomerization of cis peptide bonds 
that convert proline residues into trans configuration, 
mainly by PPIase B24 (FIG. 3c). When most of the helix is 
folded, the N­propeptides associate and form the small 
triple helix within this domain. The newly formed triple 
helix is stabil ized by serpin H1 (also known as HSP47; 
encoded by SERPINH1) and FKBP65 (REFS 25–27). 
Further modifi cations occur during transport from the 
rER to the Golgi apparatus in special coat protein com­
plex vesicles that contain melanoma inhibitory activity 
protein 3 (also known as TANGO1) and through the 
Golgi stack by cisternal maturation. Serpin H1 also has 
binding sites along the helical portion of the molecule 
and assists shuttling of folded collagen into the cis­
Golgi25–27. These biosynthetic steps depend on a proper 
rER environment (for example, optimal calcium levels 
and redox potential), and the quality­control mech­
anisms can lead to the activation of the unfolded protein 
response using the ER­associated degrad ation pathway 
or the autophagy­mediated lyso somal degradation sys­
tem to eliminate molecules that were not properly folded. 
Once secreted, the propeptides of procollagen are cleaved 
by a disintegrin and metalloproteinase with thrombo­
spondin motifs 2 (ADAMTS2) and bone morpho genetic 
protein 1 (BMP1) into mature type I collagen. This initi­
ates collagen fibre formation and these fibrils are stabil­
ized by crosslink formation, in which certain lysine and 
hydroxy lysine residues in the triple helix and the telo­
peptides are oxidized by lysyl oxidases and converted 
into allysine and hydroxyallysine. These residues then 
initially form  divalent crosslinks that convert into mature 
trivalent pyridinoline and pyrrole crosslinks to stabilize 
the fibril structure in  tissues (FIG. 3d).
Structural and quantitative collagen defects. Mutations 
in COL1A1 and COL1A2 can result in the synthesis of 
a reduced amount of normal type I collagen (quantita­
tive defect) or in the production of collagen molecules 
with altered structure (structural defect)1. Quantitative 
defects are associated with the milder osteogenesis 
imperfecta type I, whereas structural collagen defects 
can cause the full range of moderate and progressive 
deforming type IV and type III, respectively, as well as 
lethal type II28 (BOX 1; TABLE 1).
Structural mutations can lead to prolonged retention 
of the unfolded α(I)­chains in the ER, resulting in exces­
sive modification of the collagen chains by exposing 
them to the post­translational­modifying enzymes for 
a longer time17. These overmodified collagen molecules 
assemble into abnormal fibrils, which results in aberrant 
extracellular matrix — one of the key features under­
lying bone fragility in osteogenesis imperfecta. In some 
cases, the abnormal collagen is partially retained in the 
ER, which causes ER stress and has been associated 
with autophagy stimulation, apoptosis activation and 
impaired osteoblast differentiation29–32. These abnor­
malities exacerbate matrix dysfunction and decrease 
collagen synthesis, which decreases bone mass29.
The most common mutations causing structural 
colla gen defects are single­nucleotide variants, substitu­
ting the glycine within the Gly­Xaa­Yaa repeat with a 
bulkier or charged residue. Some structural collagen 
defects (20–25%) are due to mutations in the 3ʹ or 
5ʹ splice sites that are responsible for exon skipping 
Figure 1 | Clinical features associated with osteogenesis imperfecta. Patients with 
osteogenesis imperfecta can present with an array of secondary features: blue sclerae 
(part a); dentinogenesis imperfecta (part b) characterized by dentin dysplasia, which 
results in weak and discoloured teeth; limb deformities (part c); pectus carinatum chest 
deformity (part d; also known as pigeon chest); clinodactyly (part e) characterized by an 
abnormal curvature of the fingers; and scoliosis (part f), as shown by the abnormal 
curvature of the spine. Images courtesy of M. Balasubramanian, University of Sheffield, 
Sheffield Children’s NHS Foundation, UK.
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in COL1A1 and COL1A2 (REF. 1). If discrete collagen 
exons are skipped, the Gly­Xaa­Yaa triplet pattern is 
not altered, but chain alignment can be shifted, which 
affects folding and secretion33. Fewer than 5% of the 
mutations occur in the C­propeptide domain of pro­
collagen, impairing chain association and/or causing 
folding delay34. An interesting and distinct group of 
helical structural defects are the consequence of dupli­
cation or deletion of one or two Gly­Xaa­Yaa triplets. 
Such mutations cause a register shift of the chains in the 
heterotrimeric mol ecule and are  associated with lethal 
or severe osteogenesis imperfecta35.
Table 1 | Genetic classification of osteogenesis imperfecta
Mutated gene Encoded protein Osteogenesis 
imperfecta 
type based on 
the genetic 
classification
Inheritance OMIM Clinical characteristics
Impairment of collagen synthesis and structure
COL1A1 or 
COL1A2
Collagen α1(I) (COL1A1) or α2(I) 
(COL1A2)
I, II, III or IV* AD • 166200
• 166210
• 259420
• 166220
Classic phenotype (see BOX 1)
Compromised bone mineralization
IFITM5 Bone‑restricted interferon‑induced 
transmembrane protein-like protein 
(BRIL; also known as IFM5)
V AD 610967 Normal-to-severe skeletal deformity, 
intraosseous membrane ossifications, 
radiodense band and radial head 
dislocation, normal-to-blue sclerae 
and sometimes hearing loss
SERPINF1 Pigment epithelium-derived factor 
(PEDF)
VI AR 613982 Moderate-to-severe skeletal deformity, the 
presence of osteoid, fish-scale appearance of 
lamellar bone pattern and childhood onset
Abnormal collagen post-translational modification
CRTAP Cartilage‑associated protein (CRTAP) VII AR 610682 Severe rhizomelia with white sclerae
P3H1 (previously 
known as LEPRE1)
Prolyl 3-hydroxylase 1 (P3H1) VIII AR 610915
PPIB Peptidyl-prolyl cis–trans isomerase B 
(PPIase B)
IX AR 259440 Severe bone deformity with grey sclerae
Compromised collagen processing and crosslinking
SERPINH1 Serpin H1 (also known as HSP47) X AR 613848 Severe skeletal deformity, blue sclerae, 
dentinogenesis imperfecta, skin 
abnormalities and inguinal hernia
FKBP10 65 kDa FK506‑binding protein 
(FKBP65)
XI AR 610968 Mild-to-severe skeletal deformity, normal- 
to-grey sclerae and congenital contractures
PLOD2 Lysyl hydroxylase 2 (LH2) No type AR 609220 Moderate-to-severe skeletal deformities 
and progressive joint contractures
BMP1 Bone morphogenetic protein 1 
(BMP1)
XII AR 614856 Mild-to-severe skeletal deformity and 
umbilical hernia
Altered osteoblast differentiation and function
SP7 Transcription factor SP7 (also known 
as osterix)
XIII AR 613849 Severe skeletal deformity with delayed 
tooth eruption and facial hypoplasia
TMEM38B Trimeric intracellular cation channel 
type B (TRIC‑B; also known as TM38B)
XIV AR 615066 Severe bone deformity with normal-to-blue 
sclerae
WNT1 Proto-oncogene Wnt-1 (WNT1) XV • AR
• AD
• 615220
• Unknown
Severe skeletal abnormalities, white sclerae 
and possible neurological defects
CREB3L1 Old astrocyte specifically induced 
substance (OASIS; also known as 
CR3L1)
XVI AR 616229 Severe bone deformities
SPARC SPARC (also known as osteonectin) XVII AR 616507 Progressive severe bone fragility
MBTPS2 Membrane-bound transcription 
factor site-2 protease (S2P)
XVIII XR Unknown Moderate-to-severe skeletal deformity, 
light blue sclerae, scoliosis and pectoral 
deformities
AD, autosomal dominant; AR, autosomal recessive; OMIM, Online Mendelian Inheritance in Man (OMIM) database (https://www.omim.org); XR, X‑linked recessive. 
*Classic types of osteogenesis imperfecta, as outlined in BOX 2.
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The position of the mutations along the chain, 
the nature of the substituting amino acid as well as the 
particular chain in which the substitution occurs 
affect clinical outcome1. Owing to the C­terminal to 
N­terminal end direction of the zipper­like folding 
of the three α­chains (FIG. 3c), mutations in the triple 
 helical N­terminal 200 residues minimally disturb 
helix formation and are generally associated with non­ 
lethal phenotypes, whereas mutations in the C­terminal 
 helical region cause both lethal and moderate outcomes. 
Substitutions with branched­chain or charged amino 
acids are responsible for severe phenotypes. In gen­
eral, a smaller proportion of mutations in COL1A2 
cause lethal osteogenesis imperfecta than do muta­
tions in COL1A1, often attributed to the type I colla­
gen stoichio metry that implies the presence of a mutant 
chain in 75% and 50% of collagen triple helices from 
defects in α1 and α2, respectively. The three major 
ligand­binding regions (MLBRs; FIG. 2) identified along 
the α1(I)­chain36 are particularly important for matrix 
quality. The C­terminal MLBR3 is especially crucial for 
interactions of collagen with extracellular matrix pro­
teins; substitutions in this domain impair extracellular 
matrix organization and have predominantly lethal out­
comes36,37. Mutations in the C­propeptide that impair 
α­chain recognition are responsible for ER­associated 
protein degradation activation, which favours the 
removal of unassembled chains29. In the α2(I)­chain, 
lethal regions that align with proteoglycan­binding sites 
on collagen fibrils have been identified along the chain; 
mutations in these domains may severely affect proper 
matrix assembly36,37.
Collagen processing defects. Extracellular cleavage of the 
propeptide is necessary for spontaneous collagen assem­
bly and the formation of fibrils and fibres in the extra­
cellular space38 (FIGS 2,3). Dominant mutations affecting 
either the C­propeptide or N­propeptide cleavage sites or 
recessive mutations affecting the activity of the enzymes 
catalysing cleavage (that is, BMP1 and ADAMTS2) result 
in distinctive phenotypes (TABLE 1).
Dominant mutations affecting the first 90 N­terminal 
amino acids of the collagen helix in either the α1(I)­chain 
or in the α2(I)­chain alter the tertiary structure of the 
N­propeptide cleavage site without altering its sequence, 
which makes the site unrecognizable as an ADAMTS2 
substrate. The resulting pN­collagen (that is, the mature 
collagen with the N­propeptide attached) assembles into 
small diameter fibrils with regular borders39,40. Retention 
of the N­propeptide in the collagen molecule might also 
compromise the intracellular functions of the pro peptide, 
such as protein phosphorylation, collagen synthesis 
and cell adhesion41,42. Furthermore, the N­propeptide 
in the extracellular matrix binds to specific cytokines 
(for example, transforming growth factor­β1 (TGFβ1) 
and BMP2), which are crucial for bone development42. 
Mutations that remove the N­terminal cleavage site 
residues due to exon skipping43 cause Ehlers–Danlos 
 syndrome, and not  osteogenesis imperfecta (BOX 2).
Dominant mutations that affect the α1(I) and α2(I) 
C­terminal cleavage site or recessive mutations that 
cause defects in BMP1 (FIG. 2) result in the presence 
of pC­ collagen (that is, the mature collagen with the 
C­propeptide attached) in the extracellular matrix44–47. 
Mutations that impair the cleavage site of the C­pro­
peptides cause a mild osteogenesis imperfecta with 
 normal or increased z­scores (indicating normal or 
increased bone mineral density) measured by dual­ 
energy X­ray absorptio metry. Mutations in BMP1 result 
in more­severe forms of osteogenesis imperfecta than 
cleavage site mutations, as BMP1 broadly affects extra­
cellular matrix assembly and structure by processing 
the C­propeptides of type I and type III collagen48,49, 
N­propeptides of pro­α1(V) and pro­α1(XI)50,51, cleavage 
of the collagen and elastin crosslinking enzyme pro­lysyl 
oxidase52 and of small leucine­rich proteoglycans, such 
as prodecorin and probiglycan53,54. BMP1 is also respon­
sible for the activation of multiple cytokines, such as 
TGFβ1, BMP2 and BMP4 (REF. 55). The presence of pC­ 
collagen affects fibril structure, favouring an abnormal 
high mineraliza tion that is associated with bone fragility 
and leads to a paradoxical high bone mass osteogenesis 
imperfecta. Hypermineralization might be the conse­
quence of increased inter­fibrillar spacing and a direct 
effect of pC­collagen as a mineral nucleator. Mutations 
that cause substitution in the cleavage site residues in 
pro­α1(I) cause fibrils with limited blebbing and almost 
normal diameter, whereas substitutions in pro­α2(I) 
cleavage site residues yield thin fibres with multiple blebs, 
probably owing to protruding C­propeptide, which may 
be  differentially digested by nonspecific proteases44.
Defects in collagen post-translational modification. 
The crucial role of post­translational modification and 
proper folding of type I procollagen in the patho genesis 
of osteogenesis imperfecta emerged from the identifi­
cation of patients with recessive mutations in genes 
encoding proteins that have an important role in these 
processes, for example, CRTAP13,56, P3H1 (REF. 57) and 
PPIase B58 (FIG. 3; TABLE 1).
Box 1 | Classification of osteogenesis imperfecta
The classic classification of osteogenesis imperfecta — proposed by Sillence et al.134 
in 1979 — has been the standard for over two decades. Sillence types I–IV are typically 
regarded as classic osteogenesis imperfecta. They are caused by dominantly inherited 
mutations in genes encoding type I collagen (COL1A1 and COL1A2), and classification 
is based on clinical presentation, radiographic features and patterns of inheritance.
• Type I: characterized by blue sclerae, near-normal stature, and late-onset hearing loss, 
but without apparent dentinogenesis imperfecta
• Type II: a perinatally lethal form
• Type III: a progressive deforming variety
• Type IV: characterized by white sclerae, short stature, bone deformity and 
dentinogenesis imperfecta, which is more severe than type I but less severe than 
type II and type III
Genetic understanding of osteogenesis imperfecta has led to two new approaches to 
classification: a more clinically based approach in which the new recessive types are put 
under the Sillence-type clinical umbrella, or a genetic–functional approach in which 
the Sillence types I–IV are reserved for mutations in COL1A1 or COL1A2 and new genes 
are given additional type numbers based on the mutation without clinical correlation. 
We use this genetic classification — outlined in TABLE 1 — when referring to 
osteogenesis imperfecta types throughout.
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Homozygous or biallelic CRTAP­null mutations56 
were identified in patients displaying a phenotype that 
overlapped with, but was distinct from, osteogenesis 
imperfecta type II and type III (BOX 1). CRTAP defici ency 
causes a severe­to­lethal osteochondro dysplasia with 
rhizomelia (that is, a disproportion of limb segments, 
in which the proximal segment is relatively short), 
neonatal fractures, broad undertubulated (that  is, 
cylindrical configuration from lack of  diaphyseal 
model ling) long bones and fragile ribs. Occasional 
survivors have severe growth deficiency and popcorn 
calcifications of epiphyses. CRTAP deficiency causes 
severely reduced hydroxylation of proline 986 of the 
α1(I)­chain and delayed helix folding and consequent 
over modification of the type I collagen helical region 
by LH1 and P4H1 (REFS 13,56). Crtap­knockout mice 
exhibit a severe osteochondrodysplasia13.
Absence of either CTRAP or P3H1 results in the 
absence of the activity of both59 because the proteins are 
mutually protective (FIG. 3). As such, P3H1­null muta­
tions give rise to a phenotype that is clin ically indis­
tinguish able from CRTAP deficiency. Biochemi cally, 
severely reduced hydroxylation of proline 986 of the 
α1(I)­chain and type I collagen overmodification57,60,61, 
and an unantici pated 50% increase in collagen prod­
uction versus controls are observed in patients with 
P3H1 mutations57.
Defects in PPIase B (FIG. 3) result in a more variable 
clinical and biochemical phenotype that overlaps with 
that caused by CRTAP and P3H1 mutations, except 
for the absence of rhizomelia58,61–63. In two patients, 
a moderate osteogenesis imperfecta phenotype was 
described64, which was associated with normal 3­hydroxy­
lation of proline 986 of the α1(I)­chain and normal heli­
cal folding, whereas in others, hydroxylation of proline 
986 of the α1(I)­chain was reduced to a lesser extent than 
patients with CRTAP and P3H1 deficiency, and colla­
gen overmodification was observed58. These findings 
suggest that collagen modification is dependent on the 
PPIB mutation.
Defects in collagen chaperones and crosslinking. When 
folding of the major helix is completed, molecular 
chaper ones (serpin H1 and FKBP65) interact with type I 
procollagen to prevent premature fibril formation within 
the rER24,65,66 (FIG. 3). Serpin H1 stabilizes the folded pro­
collagens in the rER and assists their shuttling into the 
cis­Golgi25–27. FKBP65 also has PPIase activity24.
Only four different homozygous SERPINH1 missense 
mutations have been described, one in Dachshunds and 
three in humans, all resulting in moderate­to­severe 
osteogenesis imperfecta67 (TABLE 1). These mutations 
are located in the serine­type endopeptidase inhibitor 
domain of serpin H1, which is crucial for chaperone func­
tion, leading to intracellular retention of type I collagen. 
In affected humans and dogs, 3­hydroxylation of pro­
line 986 of the α1(I)­chain is normal. Post­translational 
overmodification of type I collagen is absent in humans 
but present in dogs, which also show abnormal collagen 
crosslinks in bone and ER stress68. The milder pheno­
type in humans probably results from residual serpin H1 
function. Serpinh1‑null mice are embryonically lethal69, 
owing to aggregation of improperly folded collagen in the 
rER, delayed collagen  secretion and eventually defective 
collagen fibrillogenesis70.
Defects in FKBP65 result in a range of overlapping 
phenotypes, including moderate­to­severe osteogenesis 
imperfecta, Bruck syndrome (characterized by severe 
osteogenesis imperfecta with congenital contractures) 
and Kuskokwim syndrome (congenital contractures 
with minimal skeletal involvement)15,61,71–78. Remarkable 
phenotypic variability is observed, even within families. 
Collagen secreted from FKBP65­defective cells shows 
normal 3­hydroxylation of proline 986 of the α1(I)­
chain and normal­to­only­slightly overmodified helical 
modifications, but C­telopeptide lysine residues that are 
crucial for collagen crosslinking18,79 are severely under­
hydroxylated76. The hydroxylation of C­telopeptide 
lysine residues is catalysed by LH2, deficiency of which 
mainly leads to Bruck syndrome, but also to forms of 
recessive osteogenesis imperfecta without contrac­
tures80–82. How FKBP65 decreases LH2 activity is not yet 
understood. Deficiency of the FKBP65 chaperone or 
PPIase functions may block the activation of LH2 or the 
telopeptide structure76.
Defects in bone formation and mineralization
Impaired bone mineralization. Some types of osteo­
genesis imperfecta are not caused by mutations that 
affect the collagen pathway itself, but by mutations 
in genes involved in bone mineralization and in the 
 differentiation of osteoblasts (FIG. 4; TABLE 1).
Figure 2 | Structure of collagen. Type I collagen is a heterotrimer composed of two α1 
and one α2 left‑handed polyproline II‑like chains that are assembled into a right‑handed 
triple helix. It is synthesized as a procollagen, containing both amino‑terminal and 
carboxyl-terminal propeptide sequences, which are proteolytically cleaved by specific 
proteases (a disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS2) 
and bone morphogenetic protein 1 (BMP1), respectively) that recognize a sequence 
in the telopeptides, that is, p.Pro161Gln162 in α1(I) and p.Ala79Gln80 in α2(I) for 
the N‑terminal cleavage sites, and p.Ala1218Asp1219 and p.Ala1119Asp1120 for the 
C-terminal cleavage sites242. The sequence of each collagen chain is characterized by 
Gly‑Xaa‑Yaa repeats (in which X and Y can be any amino acid (AA) but are most often 
proline and hydroxyproline). Glycine is required at every third position and is tightly 
packed at the centre of the triple helical structure. Collagen contains ~20% proline 
residues. The post‑translational 4‑hydroxylation of most prolines in the Yaa position is 
required for triple helical stability243. Along the α1-chain, specific regions that are relevant 
for the interaction of collagen with other collagen molecules or with extracellular matrix 
proteins were identified, namely, major ligand‑binding region (MLBR).
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N
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Osteogenesis imperfecta type VI is caused by reces­
sive null mutations in SERPINF1, which encodes 
 pigment epithelium­derived factor (PEDF). PEDF is 
an anti­angiogenic factor that also interacts with recep­
tor activator of nuclear factor­κβ ligand (RANKL; also 
known as TNFSF11) pathway, thereby increasing the 
activity of osteoclasts83–85 (FIG. 4a). Absence of PEDF leads 
to broad osteoid (unmineralized bone matrix) seam in 
bone, which indicates delayed mineralization.
Osteogenesis imperfecta type V is caused by a recur­
ring dominant mutation in the 5′ untranslated region 
of IFITM5, creating a new start codon and elongating 
the N terminus of bone­restricted interferon­induced 
transmembrane protein­like protein (BRIL; also known 
as IFM5) by five amino acids. Type V is the only domin­
ant type of osteogenesis imperfecta beside the classic 
types caused by mutations in COL1A1 and COL1A2 
(REFS 86,87). BRIL seems to have a crucial role during 
bone mineralization. Interestingly, mutations in the gene 
that encodes BRIL seem to have a gain­of­function effect 
if the protein is elongated, inducing increased bone for­
mation, which leads to hyperplastic callus and ossifica­
tion of membranes, whereas mutations in the coding 
regions impair mineralization of bone86,88.
The interaction between PEDF and BRIL became evi­
dent in patients with a p.S40L substitution in IFITM5. 
These patients presented with a severe atypical clinical 
course and histomorphometric and laboratory findings 
consistent with patients with osteogenesis imperfecta 
type VI88,89. The amount of osteoid was increased and 
the production of PEDF in osteoblasts was decreased. 
These findings support the hypothesis that BRIL and 
PEDF interact in the process of osteoblast development, 
osteoid formation and mineralization, but the exact 
mechanisms remain to be elucidated.
Patients with osteogenesis imperfecta type V have 
overall brittle bone with a similar severity compared 
with patients with osteogenesis imperfecta type IV, but 
bone abnormalities are marked by a triad of hyperplastic 
callus formation, radiodense lines at the epiphyses and 
calcification of the interosseous membrane of the fore­
arm90. Patients with osteogenesis imperfecta type V may 
also have radial dislocation, but do not have the scleral or 
 dental findings of osteogenesis imperfecta associated with 
defects in the quantity, structure or processing of type I 
collagen. Bone tissue histomorphometry is also distinct, 
with a mesh­like lamellation pattern under polarized 
light. By contrast, patients with osteogenesis imperfecta 
Figure 3 | Type I collagen synthesis and processing. a | Translation and 
post-translational modifications of pro-α1(I) and pro‑α2(I). b | Interactions 
with molecular chaperones to prevent premature triple helix formation. 
c | Triple helix formation that comprises two pro‑α1-chains and one 
pro-α2-chain. d | Secretion of procollagen, extracellular cleavage to 
collagen and crosslinking. ADAMTS2, a disintegrin and metalloproteinase 
with thrombospondin motifs 2; BMP1, bone morphogenetic protein 1; 
CRTAP, cartilage‑associated protein; GLT, galactosyltransferase 1; InsP3R, 
inositol‑1,4,5‑triphosphate receptor; LH, lysyl hydroxylase; P3H1, prolyl 
3‑hydroxylase 1; P4H1, prolyl 4‑hydroxylase 1; PPIase B, peptidyl‑prolyl 
cis–trans isomerase B; rER, rough endoplasmic reticulum; TANGO1, 
transport and Golgi organization protein 1; TRIC‑B, trimeric intracellular 
cation channel type B. *Mutations in the genes encoding these proteins are 
associated with osteogenesis imperfecta.
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type VI are mostly mildly affected at birth, exhibit pro­
gressive brittle bone disease and often have considerable 
increased serum levels of alkaline phosphatase (a marker 
for osteoblast activity) in childhood. Their bone histo­
morphometry is distinct, with increased amounts of 
unmineralized osteoid and a fish­scale pattern under 
polarized light. Patients with osteogenesis  imperfecta 
type  VI have a poor response to  bisphosphonate 
(an anti­resorptive) treatment91.
Defects in osteoblast differentiation and function. Genes 
involved in osteoblast differentiation have recently been 
associated with osteogenesis imperfecta, although, for 
most, the underlying pathogenetic mechanism remains to 
be determined (TABLE 1). A hypomorphic mutation (partial 
loss of function) in SP7, encoding the osteoblast­specific 
transcription factor SP7 (also known as osterix), which 
is essential for bone formation, was described in a child 
with recessive osteogenesis imperfecta92. Sp7­null mice 
show deficient osteoblast differentiation and proliferation, 
and reduced expression of osteoblast markers93.
Defects in trimeric intracellular cation channel 
type B (TRIC­B; also known as TM38B and encoded by 
TMEM38B) were found in patients with moderate osteo­
genesis imperfecta14,94 (FIG. 4b). TRIC­B is a monovalent 
cation­specific channel that is necessary for intracellu­
lar calcium flux and is involved in cell differentiation95. 
Tmem38b−/− mice are neonatally lethal and have reduced 
bone volume95,96. Defective ER calcium flux dysregulates 
collagen synthesis by multiple ER enzymes94,97 (FIG. 3d).
Homozygous mutations in WNT1 were identified 
in patients with moderate­to­severe, progressive osteo­
genesis imperfecta. Heterozygous WNT1 mutations 
lead to osteoporosis16,98–100. WNT1 interacts with the 
receptor Frizzled and its co­receptor low­density lipo­
protein receptor­related protein 5/6 (LRP5/6) to activate 
bone formation101,102 (FIG. 4b). Homozygous or biallelic 
LRP5 loss­of­function mutations cause osteoporosis­ 
pseudoglioma syndrome103–105, whereas heterozygous 
gain­of­function mutations cause van Buchem disease 
type 2 (or endosteal hyperostosis)106. Wnt1−/− mice are 
embryonically lethal and have severe brain abnormalities 
but no reported skeletal phenotype, whereas the Swaying 
mouse (which is homozygous for a single­ nucleotide 
deletion in Wnt1 in exon 3) survives post natally, has 
severe osteopenia and a cerebellar defect, similar to some 
human WNT1 mutations99,107.
Finally, two genes encoding proteins that are part of 
the regulated intramembrane proteolysis (RIP) pathway 
in osteoblasts have been reported to cause osteo genesis 
imperfecta (FIG. 4b). In RIP, the endopeptidases S1P 
(encoded by MBTPS1) and S2P (encoded by MBTPS2, 
the first identified X­linked gene for osteogenesis imper­
fecta) in the Golgi membrane sequentially cleave regu­
latory proteins transported from the ER membrane 
in times of ER stress or sterol metabolite deficiency. 
Mutations that cause single­residue substitutions in or 
near the ion­coordination site of S2P, and impair its 
cleavage of substrate transcription factors, have been 
reported in two pedigrees with moderate­to­severe 
osteogenesis imperfecta. Hydroxylation of lysine 87 of 
the α1(I)­chain and α2(I)­chain is reduced, collagen 
crosslinking is altered and bone strength is impaired in 
bone tissues of patients with MBTPS2 mutations108. One 
of the transcription factors activated by RIP is old astro­
cyte specifically induced substance (OASIS; encoded by 
CREB3L1) (FIG. 4b). Deficiency of OASIS was reported in 
a family with severe­to­lethal osteogenesis imperfecta109. 
OASIS is an ER stress transducer that regulates the tran­
scription of genes involved in developmental processes, 
differentiation and maturation. Creb3l1−/− mice dis­
play severe osteopenia with spontaneous fractures and 
decreased type I collagen production in bone110.
Bone tissue characteristics
The hallmark feature of osteogenesis imperfecta is high 
bone fragility that arises from low bone mass and abnor­
malities in bone material properties, such as reduced 
toughness. Alterations in bone tissue characteristics are 
surprisingly similar in most types of osteogenesis imper­
fecta. At the microscopic scale, histomorphometric stud­
ies showed that the decrease in bone mass is mirrored 
by a decrease in cortical width and  cancellous bone vol­
ume in children who have classic Sillence osteo genesis 
imperfecta (BOX 1), as well as in recessive type VII and 
type VIII. However, nearly independent of the clinical 
outcome, bone turnover is increased owing to the pres­
ence of a higher number of osteoblasts and osteoclasts, 
whereas matrix production at the single cell level is 
markedly reduced10,90,111,112.
The degree of mineralization of the bone matrix, 
determined by measurements of the bone mineraliza­
tion  density distribution using quantitative backscattered 
electron imaging, was found to be almost universally 
increased in osteogenesis imperfecta113. Consistently, 
biopsy samples from children with a mild pheno­
type and either quali tative or quantitative COL1A1 or 
COL1A2 mutations revealed a similar increase in mean 
calcium content of the bone matrix114. The same is true 
in patients with a more severe phenotype (type IV and 
type III) and in recessive type VII and type VIII112,115,116. 
Interestingly, in type VI, highly mineralized bone areas 
are surrounded by fringes that show low mineral con­
tent and abnormally mineralizing young osteocytes117. 
The increased mineral content in bone of patients with 
osteogenesis imperfecta is unchanged by bisphosphonate 
treatment112,115,118. In samples from children with mild 
osteogenesis imperfecta and from mouse models studied 
Box 2 | Ehlers–Danlos syndrome
Absence of the amino-terminal cleavage site in pro-α1(I) and pro-α2(I) causes  
Ehlers–Danlos syndrome (EDS) VIIA or VIIB, respectively, rather than osteogenesis 
imperfecta43. EDS is a connective tissue disease characterized by skin and joint laxity 
with vascular symptoms in some types. Although these patients have mild osteopenia, 
their main clinical characteristics are severe joint hypermobility, dislocations and 
ligamentous laxity. The matrix fibres contain pN-collagen (that is, the mature collagen 
with the N-propeptide attached), causing irregular borders and reduced diameter. 
Defects in ADAMTS2 cause EDS VIIC, which is associated with extreme skin fragility239. 
In this recessive condition, not only type I collagen processing but also the processing 
of other fibrillar collagen types, such as type II collagen240, are compromised, 
complicating the molecular consequence of the mutations.
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by small­angle X­ray scattering, the thickness of bone 
mineral par ticles was the same or smaller than in con­
trols119,120. The combin ation of increased matrix  mineral 
content and similar par ticle size implies that mineral par­
ticles are more­tightly packed in the extracellular matrix. 
As the extracellular matrix contains mostly collagen, the 
total space left for water between collagen molecules and 
mineral particles is decreased in osteogenesis imper­
fecta121, making the bone stiffer. Moreover, collagen 
crosslinks are altered, which is also likely to increase the 
brittleness of the bone tissue122,123.
Resistance to fracture, quantitatively determined 
in mouse models of osteogenesis imperfecta such as in 
osteogenesis imperfecta murine (oim) mice (carry­
ing a point mutation in Col1a2 in the region encoding 
the C­propeptide, preventing the incorporation of the 
α2(I)­chain into the collagen heterotrimer) and brittle 
IV (Brtl/+) mice (a point mutation in Col1a1 that causes 
the Gly349Cys substitution in the α1(I)­chain and the 
synthesis of an overmodified type I collagen), was found 
to be reduced124,125. The increased vulnerability to frac­
tures might be explained by abnormalities of the miner­
alized matrix at different levels, affecting structures that 
normally hinder crack propagation126. First, compared 
with controls, the alignment of collagen fibrils was found 
to be more disordered and less lamellar in both oim 
mouse models124,127 and biopsy samples from patients 
with osteo genesis imperfecta128; second, the collagenous 
matrix is not only reduced in amount129 but also showed 
more non­enzymatic crosslinks124; third, unmineral­
ized collagen fibrils from the oim mouse model showed 
reduced strength under tensioning130 and more affinity to 
water131. By contrast, less tissue water was found in fully 
mineralized bone of the oim mice132 and in bone biop­
sies from patients with osteogenesis imperfecta121. Last, 
this is in good agreement with the increased amount of 
mineral in the matrix, corresponding to a higher density 
of  thinner mineral platelets in both oim mouse mod­
els124,127 and patients with osteogenesis imperfecta120. The 
 cooperative effect of these secondary defects on bone 
fragility is probably more important than the collagen 
mutation itself, as discussed in a recent review133.
Mechanical testing shows that bone is generally less 
stiff, allowing it to bend with less force and reducing the 
load to reach a point of non­recoverable deformity or 
fracture; these characteristic contribute to the exacer­
bation of bone deformity, just by the pull of normal 
muscle, and bone fractures. Most crucially, bone in 
osteogenesis imperfecta is a brittle tissue and cannot 
dissipate energy efficiently; although healthy bone can 
absorb energy into the extracellular matrix with advanc­
ing deformation, osteogenesis imperfecta bone snaps 
like chalk with minimal displacement133.
Diagnosis, screening and prevention
Classification
The modern era of classification of osteogenesis imper­
fecta began with clinical studies by David Sillence and 
colleagues in the late 1970s134 that recognized four dis­
tinct groups standardized as ‘types’ on the basis of clin­
ical presentation, radiographic features and patterns of 
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Figure 4 | Defects in bone formation and mineralization in osteogenesis 
imperfecta. a | Bone remodelling. Bone formation consists of the secretion of bone 
extracellular matrix components (mainly type I collagen) by osteoblasts. The 
unmineralized bone matrix (osteoid) subsequently becomes mineralized. In addition, 
osteoblasts and osteocytes release many cytokines, including receptor activator of 
nuclear factor-κB ligand (RANKL; also known as TNFSF11) and osteoprotegerin (OPG), 
which regulate bone resorption by osteoclasts. RANKL acts on osteoclast precursor 
cells by binding to receptor activator of nuclear factor-κB (RANK; also known as 
TNFRSF11A) on their surface, thereby favouring their differentiation to osteoclasts. 
OPG, by interacting with RANKL, prevents the binding of RANKL to RANK. Some 
osteoblasts become embedded in the mineralized bone matrix and differentiate to 
osteocytes, which produce, among other factors, sclerostin, an inhibitor of the WNT 
pathway that is known to stimulate bone formation by stimulating osteoblast activity. 
b | WNT1 is a secreted ligand that stimulates the transcription of genes involved in 
osteoblast differentiation by interacting with the receptors low-density lipoprotein 
receptor‑related protein 5/6 (LRP5/6) and Frizzled on osteoblast precursor cells. 
Endopeptidase S2P is a protease in the Golgi membrane that is involved in regulated 
intramembrane proteolysis (RIP) of transcription factors, such as old astrocyte 
specifically induced substance (OASIS), which is transported from the endoplasmic 
reticulum (ER) membrane for processing in times of ER stress. Pigment epithelium‑ 
derived factor (PEDF) is a multifunctional secreted protein with anti-angiogenic 
activity; bone‑restricted interferon‑induced transmembrane protein‑like protein (BRIL) 
is a transmembrane protein involved in mineralization. Crosstalk between the two 
proteins had been elucidated following mutations identified in patients with 
osteogenesis imperfecta. Dashed lines indicate unknown pathways. InsP3R, inositol‑ 
1,4,5‑triphosphate receptor; OASIS‑N, N‑terminal part of OASIS; MALEP, methionine, 
alanine, leucine, glutamate and proline pentapeptide; S40L, p.Ser40Leu substitution; 
TRIC‑B, trimeric intracellular cation channel type B; VEGF, vascular endothelial 
growth factor. *Mutations in the genes encoding these proteins are associated 
with osteogenesis imperfecta.
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inheritance. After the past decade of advances in genet­
ics, two approaches to classification have evolved (BOX 1). 
We use the genetic–functional approach, in which the 
Sillence types I–IV (classic osteogenesis imperfecta) are 
reserved for mutations in COL1A1 or COL1A2, and new 
genes are given additional type numbers (TABLE 1).
One of the advantages of the genetic classification 
is that patients and families know the cause of the dis­
ease and they quickly understand that not all types are 
the same, even though they have common features. 
A genetic classification provides an inheritance pattern 
for counselling, and functional groupings for natural 
history and treatment research. Unlike in a clinical 
classification, the genetic ‘type’ of an individual will not 
change as they age or between family members. The 
Online Mendelian Inheritance in Man database has 
used a mixed classification, with types I–IV according 
to the Sillence classification134, and the remainder clas­
sified by type number and gene with some elements of 
clinical differentiation. The Osteogenesis Imperfecta 
Foundation has adopted a genetic–functional classifi­
cation based on Forlino et al.4, in which genes are 
linked to numerical types and grouped by similarity of 
 function (TABLE 1).
By contrast, the advantages of the clinical classifi­
cation are that most assessments and decisions about 
treatment are made on clinical grounds (even though 
there is evidence that bisphosphonates, for example, are 
less effective in individuals with mutations in SERPINF1 
and with some mutations in other genes) and so the 
value of gene­based classification may be limited. This 
has led to the creation of a classification based largely 
on the ability to identify groups on clinical grounds 
(clinical classification) suggested by the working 
group of the International Skeletal Dysplasia Society, 
with subclasses defined by the pattern of inheritance 
and the host gene135. An additional type was added 
— type V — character ized by osteogenesis imper­
fecta with calcification of the interosseous membranes 
and/or hypertrophic callus.
Classification of the different types of osteogenesis 
imperfecta is still debated, in particular, the generation 
of a classification scheme that does not change criteria 
for emerging types.
Diagnosis
The diagnosis of osteogenesis imperfecta usually depends 
on clinical presentation (FIG. 1), including a (prenatal) 
fracture (or fractures) or family history. Some types can 
be diagnosed prenatally, whereas others only become 
apparent at birth or in early childhood. Screening for 
osteogenesis imperfecta on clinical grounds is sometimes 
initiated as part of the assessment of unexpected frac­
tures in infants and young children, with confirmation by 
genetic testing. Genetic testing of children with an initial 
diagnosis of non­accidental injury or abuse identified 
11 out of 262 children with collagen abnormalities in a 
retrospective analysis, 6 of whom were suspected to have 
osteogenesis imperfecta by referring physicians136.
Clinical examination and review of radiographs of 
long bones and the skull, as well as evaluation of denti­
tion provide the bases for clinical diagnosis. Signs of a 
generalized connective tissue disorder (such as short 
stature, relative macrocephaly, blue sclerae, character­
istic facial or thoracic configuration, hearing loss, 
scolio sis and sarcopenia) are variable, but are taken into 
account. Depending on the setting, the diagnosis can be 
 confirmed by genetic tests.
Use of next­generation sequencing approaches with 
panels of all known genes associated with osteo genesis 
imperfecta facilitates rapid diagnosis. If mutations of 
uncertain function are detected, gel electro phoretic 
analy sis of collagen produced by cultured dermal 
fibroblasts from postnatal skin biopsies can be used 
to establish function; for example, biochemical analy­
sis can detect alteration in the amount, structure or 
post­ translational modification of type I procollagen in 
osteo genesis imperfecta type I (relatively reduced type I 
versus type III collagen levels), most cases of types II, III, 
IV, VII and VIII (collagen overmodification), as well as 
type XIV (undermodification). In rare instances when 
gene sequencing does not identify a mutation, a single 
or multi­exon deletion in COL1A1 and COL1A2 can be 
detected by multiplex ligation­dependent probe amplifi­
cation or by marked overmodification of the chains of 
type I procollagen137.
Screening
Routine screening for osteogenesis imperfecta is gener­
ally limited to prenatal ultrasonography imaging (FIG. 5), 
which can detect the perinatally lethal forms of osteo­
genesis imperfecta by 14–16 weeks of gestation, even in 
the absence of family history of the disease. Type III can 
be identified by ~18 weeks of gestation when longitudi­
nal growth falls too close to the 5th percentile. Although 
this has not been reported, in principle, severe recessive 
cases should be detectable prenatally by ultrasonography. 
Sequencing of chorionic villus samples is sometimes 
used prenatally to confirm osteogenesis imperfecta in 
 individuals with a family history of the disease.
Identification of a fetus with severe limb shortening 
and fractures provides information for potential early 
pregnancy termination after genetic confirmation or 
delivery management. Preimplantation genetic diag­
nosis is available for families in which a parent has a 
domin antly inherited form of osteogenesis imperfecta, 
Figure 5 | Prenatal screening for osteogenesis imperfecta. Ultrasonography images 
of two fetuses at 32 weeks (part a) and 33 weeks (part b) of gestation with genetically 
proven osteogenesis imperfecta demonstrating a severe bowing of the femur (arrows) 
in both cases and probably an intrauterine fracture in one of them (part a).
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for parents who are each carriers of a recessive form, 
and for families in whom parental mosaicism for a 
domin ant form has been identified in one parent 
( usually because of parental testing after the identifica­
tion of an affected fetus or infant in which genetic stud­
ies identified the causative gene and mutation). For those 
famil ies, embryos that result from in vitro fertilization 
can be screened, and those not at risk to develop the 
disorder can be selected. Use of eggs or sperm from an 
unaffected individual can be used to assure that parental 
 osteogenesis imperfecta is not transmitted.
Management
No cure exists for osteogenesis imperfecta. Management 
is symptom­based and depends on the type and severity 
of complications.
Musculoskeletal interventions
The wide clinical range of osteogenesis imperfecta, 
from severe short stature and bony deformities to very 
mild forms without fractures, leads to specific musculo­
skeletal challenges (BOX 1; TABLE 1). Features such as 
long bone bowing, joint laxity, and decreased range of 
motion and muscle strength can lead to delayed motor 
milestones, reduced mobility and limitations in activities 
of daily living138–140.
Musculoskeletal impairments are greater in individ­
uals with more­severe phenotypes141 (TABLE 1). Individuals 
with osteogenesis imperfecta type I are community 
ambulators, who might exhibit limitations in sports 
and physical function142,143. Muscle strength, although 
difficult to measure in people who are fearful of frac­
tures, has been reported as being reduced in those with 
osteo genesis imperfecta type I142,144. By contrast, individ­
uals with osteogenesis imperfecta type III are exercise 
ambulators, with limitations in a protected rehabilitation 
environment, whose severe upper extremity deformi­
ties affect self­care and mobility139,145,146. Grip force was 
weaker in a sample of children with different types of 
osteogenesis imperfecta than in unaffected children147, 
although the relative contributions of decreased muscle 
mass versus limited physical activity are unclear.
Musculoskeletal management of osteogenesis imper­
fecta consists of rehabilitation (pre­surgery and post­ 
surgery), surgical interventions and medical treatment.
Rehabilitation. Rehabilitation is an especially crucial 
component in the management of osteogenesis imper­
fecta. An intervention study that analysed a 12­week 
graded exercise programme showed some short­term 
improvement in muscle force, indicating the benefits 
of rehabilitation148.
For severely affected infants, initial rehabilitation 
facilitates parental bonding, by teaching parents how 
to handle a fragile baby. Later, rehabilitation focuses 
on maximizing strength, function and independence, 
and recovery from surgical procedures. Rehabilitation 
interventions are most beneficial: in infancy and early 
childhood if motor delays emerge, when overprotection 
or fear of movement prevents skills acquisition, during 
periods of transition to a new environment, and follow­
ing injury, fracture or surgery. Physical rehabilitation is 
also useful as a support to pharmacological treatments 
of bone strength. Those with good baseline motor func­
tion require less intervention, particularly patients with 
osteogenesis imperfecta type I139,149–151.
BOX 3 outlines the specific rehabilitation modalities 
and strategies that are widely used. Strengthening and 
weight bearing via aquatic therapy are strongly advo­
cated for individuals with osteogenesis imperfecta as the 
environment is safer152,153. New modalities to increase 
bone density, such as weight bearing, as well as Pilates 
classes to increase core muscle strength, are emerging154.
Orthopaedic management. The surgical management 
of osteogenesis imperfecta includes lower extremity, 
upper extremity and spine surgery, and is usually com­
bined with medical treatment and pre­surgery and 
 post­surgery rehabilitation.
Realignment with osteotomies (a surgical proce­
dure in which a bone is cut to straighten it) with intra­
medullary rodding (insertion of a metal rod into 
the medullary cavity of a bone to provide strength and 
alignment) remains the best surgical option for lower 
extremity surgery in patients with osteogenesis imper­
fecta155 (FIG. 6). Plates and screws should not be used, 
because stress might increase the risk of fracture above 
or below the plate156. Complications of rodding include 
migration of the nail outside the bone into soft tissue or 
joint space. Surgery on a child with bowed extremities 
should be performed when the child is ready to stand 
and walk. The use of telescoping rods (a compound rod 
with two segments that telescope into each other, are 
fixed by screws into bone at both ends and extend dur­
ing growth) versus regular rods remains controversial, 
and is technically more demanding and expensive than 
straight rods157. The reoperation rate with tele scoping 
rods is close to 50% compared with 58–87% with regu­
lar rods, but this number includes repeated surgery 
due to fractures or bent nails158. In addition, telescoping 
rods pose the risks of not elongating or of impacting the 
growth plate159. The choice of ‘open’ osteotomy or percu­
taneous osteotomy using a minimally invasive approach 
depends on the severity of the deformity and on the shape 
of the bone. Bilateral femurs and tibiae can be operated 
on in one surgical session, although a blood transfusion 
is likely to be necessary. Postoperative immobilization 
Box 3 | Rehabilitation strategies and modalities in osteogenesis imperfecta
• Targeted joint stretching and muscle strengthening programmes
• Weight-bearing activities and the use of ambulation aids (such as a walker, crutches 
or a cane) as required according to the amount of lower extremity strength162
• Lower extremity orthotics (such as splints and braces) to compensate for joint laxity 
or muscle weakness162,241
• Protective handling by the caregiver and positioning to avoid injuries and prevent 
contractures152
• Mobility devices such as manual or powered wheelchairs for specific environments
• Adaptive equipment to compensate for short stature, deformities and weakness152
• Environmental adaptations to the home, school or workplace to promote 
independence
• Physical fitness and healthy lifestyle coaching
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should not exceed the healing time of a normal bone. 
Bracing and rehabilitation must be planned between 
 surgeons and therapists.
Upper extremity surgery is performed more fre­
quently than in the past because upper extremity deform­
ities are now understood to affect self­care, whereas they 
were previously considered as purely  cosmetic. Indeed, 
medical treatment now enables patients to walk, for 
which they need upper extremity function, for example, 
to use walking aids. Rodding of the humerus is techni­
cally demanding because of the need to protect the radial 
nerve; either telescoping or regular rods are used160. For 
forearm deformities, elastic rods or Kirschner wires 
(metallic wires that are used to align bone segments) 
are the best implants. Osteogenesis imperfecta type V 
represents a special challenge, both because of the 
risk of postoperative hyperplastic  callus and the diffi­
culty of treating intra­articular bone deformities, such 
as radial head dislocation, hyper trophy of the mandibu­
lar coronoid  process and  extension deformity of the 
distal humerus161.
The use of bisphosphonates and consequent increase 
in bone mass and relief of vertebral compressions now 
enables the use of pedicular screws (screws inserted in 
the posterior arch and the vertebral body) and clamps, 
which give stronger fixation with reduced need for 
postoperative immobilization than hooks162. Although 
bisphosphonates have not decreased the incidence or 
extent of scoliosis, modest slowing of curve develop­
ment in severe osteogenesis imperfecta type III allows 
surgery to be performed at an older age163. Severe curv­
ature of the spine needs to be reduced before surgery 
with a halo­traction device (with multiple pin fixation).
Pharmacological treatment
Bone strength depends on bone material properties 
(quality), bone mass (amount) and bone architecture 
(distribution). The disorganized, hypermineralized bone 
matrix in osteogenesis imperfecta is not directly altered 
by any currently available pharmacological therapy133. 
However, both anti­resorptive (for example, bisphos­
phonates) and anabolic (for example, growth hormone) 
therapies might improve bone mass. It is hypothesized 
that it might be beneficial to have more bone of the same 
(poor) material quality.
Clear evidence exists that bisphosphonates improve 
bone microarchitecture164, bone mass165, long bone bow­
ing deformity166, and restore vertebral size and shape150 
in osteogenesis imperfecta. Vertebral compression was 
reduced, and areal bone density increased by about 
1.5 standard deviation (z­score) in the first treatment year 
in most paediatric placebo­controlled trials in osteogenesis 
imperfecta167. However, bisphosphonate treatment will 
not improve ligament laxity, which is a major contrib utor 
to scoliosis in osteogenesis imperfecta. In agreement with 
this, retrospective analyses of scoliosis in children with 
osteogenesis imperfecta who were treated with bisphos­
phonates showed no improvement in the incidence of 
 scoliosis at maturity, even in patients who were treated 
before 5 years of age, compared with children who had 
received no bisphosphonates165,168,169. Children with osteo­
genesis imperfecta type III had modest reduction in the rate 
of scoliosis progression in the first 2–4 years of treatment, 
but, ultimate, the incidence rate was unchanged163.
For long bone fractures, there is limited evidence for 
anti­fracture efficacy of bisphosphonates in randomized 
controlled trials in children with osteogenesis imperfecta, 
and none in adults170. Meta­analyses and two Cochrane 
reviews did not support an effect of bisphosphonate 
treatment on long bone fractures in children with osteo­
genesis imperfecta167,171,172. This finding suggests that 
improving bone architecture may not be sufficient to 
overcome the increased fracture risk owing to altered 
bone material properties, particularly in more­severely 
affected children. In fact, treatment with bisphospho­
nates increased bone brittleness in mouse models at 
the whole­bone level, perhaps by impairing microcrack 
repair and decreased mineralization heterogeneity due 
to reduced bone turn over173. In addition, concerns have 
also arisen over the long cumulative half­life of bisphos­
phonates, which are incorpor ated in the bone matrix, 
and their possible contribution to impaired healing of 
fractures and osteotomies, and delayed tooth eruption. 
Furthermore, placebo­ controlled trials did not con­
firm earlier case reports that bisphosphonate treatment 
reduced bone pain167. This finding might reflect a placebo 
effect in the case studies or might be owing to the lack of 
a  disease­specific assessment tool.
Although bisphosphonates are widely regarded as part 
of multidisciplinary management in children with osteo­
genesis imperfecta, the consensus on which drug to use, 
in what dose or for how long is lacking. The maximum 
benefit based on the assessment of bone histology174 and 
areal bone mineral density175 occurs after ~3 years of 
treatment, but many children are treated continuously 
Figure 6 | Lower extremity surgery in patients with 
osteogenesis imperfecta. Radiographic images showing 
severe curvature of the legs (part a and part c) in two 
patients with osteogenesis imperfecta, which was 
ameliorated by rodding of the long bones (part b and part d).
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until closure of the epiphyseal growth plates outside 
of research protocols. In addition, in contrast to adult 
studies of bisphosphonates in various diseases, reports 
of adverse events are few, but no systematic reporting is 
in place for  comorbidities, and few long­term follow­up 
data are available.
Extraskeletal manifestations
Although skeletal findings predominate in osteo genesis 
imperfecta, other affected tissues include pulmonary and 
cardiac systems, vasculature and dentition176. Abnormal­
ities in these systems should be monitored and treated 
according to organ­specific guidelines.
Pulmonary manifestations. Pulmonary complications 
are the leading cause of death in osteogenesis imperfecta 
and have been attributed to secondary effects of scoliosis 
and rib fractures177–179. Patients with osteogenesis imper­
fecta who have marked scoliosis can develop obstruc­
tive pulmonary disease and show progressive decline in 
pulmo nary function parameters. Thus, patients with or 
who are suspected to have vertebral or chest wall deform­
ities should be evaluated by spirometry (an analy sis of 
pulmonary function) at a minimum and be further evalu­
ated for standard pulmonary interventions. If restrictive 
or obstructive disease is identified, patients should be 
managed according to organ­specific guidelines. Recent 
evidence suggests that pulmonary function diminishes 
in osteogenesis imperfecta with age and lung disease is 
observed in individuals without scolio sis, suggesting that 
the lung defect might be intrinsic to the disease and not 
just the consequence of scoliosis178,180.
Cardiovascular manifestations. Type I collagen is a major 
component of the extracellular matrix of cardiac valves 
and the aortic wall. Thus, altered type I collagen synthe­
sis can affect their biomechanical properties181, leading, 
in rare cases, to aortic dissection182. Most commonly 
reported cardiac abnormalities are aortic root dilation183 
and left­sided valvular regurgitation, and, occasionally, 
right­sided valve pathologies184–186. Echocardiography 
should be performed in patients with scoliosis or chest wall 
deformity, heart murmurs, or any cardiac or pulmonary 
 symptomology with referral to appropriate specialists.
Bleeding diathesis. Tissue fragility and/or a bleeding 
diathesis (an unusual susceptibility to bleeding) owing 
to vessel fragility and platelet dysfunction have been 
reported in osteogenesis imperfecta187. As a consequence, 
patients with osteogenesis imperfecta can develop sub­
dural and epidural haematomas after minimal trauma 
and have a higher risk of surgical complications188,189.
Hearing loss. Half of patients with osteogenesis imper­
fecta develop hearing loss, usually between the second 
and fourth decades of life190,191. Conductive deafness is 
frequently associated with bony changes that affect the 
oval window region and lead to stapes footplate fixation 
due to thinning, atrophy and fractures of the stapes and 
the incus192. Initial conductive hearing loss can evolve 
into a mixed (conductive and sensorineural) hearing 
loss193. All patients with osteogenesis imperfecta should 
be evaluated for hearing loss on a regular basis, starting in 
childhood, and referred for hearing aids, stapes surgery 
or cochlear implants as needed.
Dental manifestations. Dentinogenesis imperfecta type I, 
a developmental disturbance of the dentin originating 
during tooth development, is associated with osteogen­
esis imperfecta caused by collagen structural defects194 
(FIG. 1b). Teeth with dentinogenesis imperfecta have a 
variable greyish­to­yellow­brown discolouration owing 
to the defective abnormal dentin shining through the 
translucent enamel. Owing to poorly mineralized dentin, 
enamel frequently fractures, which leads to rapid wear of 
the teeth even down to the gingiva195. Oral health treat­
ment includes meticulous oral hygiene and approaches 
that focus on preventing caries and  periodontal disease, 
and optimize aesthetics.
Adult management
Similar to other childhood­onset disorders, adults with 
osteogenesis imperfecta must transition their paediatric 
team care to individual adult providers who may not 
have the same levels of expertise in the condition196,197. 
Affected individuals should maintain routine health 
surveillance based on family health history risk stratifi­
cation198, and follow established screening guidelines 
for adult­onset disorders (http:// www.uspreventive­
servicestaskforce.org). As the prevalence of osteogenesis 
imperfecta in adults is low, no disease­specific treatment 
for the complications is currently available.
Because of the ongoing risk of fractures199,200, it is 
important that patients have established relationships 
with adult orthopaedic surgeons who are familiar with 
osteogenesis imperfecta. Similar to patients with osteo­
porosis, adequate intake of calcium, maintenance of 
appropriate vitamin D levels and continued mobility 
are simple adjuncts to other medical interventions201,202. 
Pharmacological treatment should be individualized for 
each patient based on the type of osteogenesis imperfecta, 
the incidence of fractures, the degree of osteoporosis 
based on imaging studies, and the absence or presence 
of menopause200,203. Joint replacement might be required, 
and is most successful with custom joints based on 
detailed imaging compared with standard­shaped joints. 
The development of progressive scoliosis might lead to 
pulmonary complications and, in rare cases, the need 
for ventilation. Baseline and follow­up with pulmonary 
function tests should be performed on all adults with 
osteogenesis imperfecta178,180.
Adults with osteogenesis imperfecta have an increased 
risk of aneurysms and dissections182,183, and deafness 
compared with age­matched controls. Cardiac evalu­
ation is important in individuals with severe progressive 
deforming osteogenesis imperfecta or with any cardio­
pulmonary symptoms185. Ongoing hearing assessments 
are also warranted to assess the need for hearing aids or 
cochlear implants193. In addition, problems related to 
dentinogenesis can have a great effect on quality of life 
(QOL)204. Skeletal pain is a frequent symptom in adults 
with osteogenesis imperfecta and should be treated in 
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a multidisciplinary approach, including orthopaedics, 
physiotherapists, psychologists and pain specialists. 
Other medical complications with increased occurrence 
in osteogenesis imperfecta include headaches associated 
with basilar invagination, glaucoma, renal manifesta­
tions, and the adverse effects of menopause on bone and 
overall health205–208.
Quality of life
The clinical features of osteogenesis imperfecta and the 
associated treatments affect health, functioning and 
QOL. The WHO defines QOL as the individual’s percep­
tion of their position in life in the context of the culture 
and value systems in which they live and in relation to 
their goals, expectations, standards and concerns209. With 
the exception of the physical functioning component of 
QOL, individuals with osteogenesis imperfecta report the 
same or better QOL (mental and psychosocial domains) 
compared with the general population210,211. Pain, frac­
tures, scoliosis, activity limitations and participation 
restrictions due to decreased function are associated 
with lower levels of physical QOL148,210–212. For those with 
pulmonary problems, life expectancy may be affected. 
Not surprisingly, physical QOL is reported as worse by 
children with more­severe osteogenesis imperfecta than 
by children who are mildly affected213. Decreased phys ical 
functioning and environmental barriers impede QOL, 
suggesting that adaptation and accessibility may have a 
positive impact. The effect of bisphosphonate treatment 
on QOL is unclear as controlled trials to date used dif­
ferent definitions and measures214–216. Anecdotal reports 
support a slight improvement in overall QOL owing to 
bisphosphonate treatment.
QOL of caregivers of children with osteogenesis 
imperfecta is lower than the general population, particu­
larly in the environmental domain, which incorporates 
the physical environment, accessibility to health and 
social care and opportunities for participation in  leisure 
activities217. This domain also differed significantly 
between parents of children with mild versus severe 
osteogenesis imperfecta. Another study using the same 
measure found no differences with population norms, 
but also reported lower scores in the environmental 
domain among parents of children with severe  compared 
with mild osteogenesis imperfecta218.
A disease­specific QOL measure is under develop­
ment, reflecting how parents, children and professionals 
working with osteogenesis imperfecta perceive the impact 
of this condition on QOL219. It will include six themes: 
being safe (avoiding impracticable activities), functioning, 
pain, fear of fracture, isolation and independence.
Outlook
Diagnosis and genetics
Prenatal sonography imaging does not always differenti­
ate osteogenesis imperfecta from hypophosphatasia 
(a rare genetic metabolic bone disease) and other skeletal 
diseases. The increasing availability of genetic panels for 
skeletal dysplasia and the use of whole­exome sequenc­
ing will increase the number of patients with genetically 
confirmed osteogenesis imperfecta. However, prenatal 
diagnosis will cause enormous ethical considerations 
for parents and physicians, increasing the importance of 
interpretation of the results220. Genetic analysis facili tates 
accurate counselling for recurrence, but the genotype– 
phenotype correlation is currently not sufficiently 
strong to counsel families regarding the prognosis of 
the  individual child34,61,220.
Management of adults
After puberty, aspects of osteogenesis imperfecta other 
than bone fractures gain more importance. In adoles­
cents and young adults, psychological problems owing 
to disability and impaired mobility, in addition to fears 
regarding their ability to lead an independent adult 
life, as well as financial and personal perspectives can 
cause symptoms of depression221. These problems are 
not exclusive to osteogenesis imperfecta and should be 
treated by psychologists who are experienced in treating 
patients with chronic diseases.
Because of the improved therapy of children with 
moderate and severe types of osteogenesis imperfecta, 
the life expectancy of patients may be extended. In a 2016 
Danish study that included all individuals with osteo­
genesis imperfecta in a national registry but excluded 
prenatally or perinatally lethal types, the all­cause mor­
tality rate among patients was nearly threefold that of the 
reference population, and life expectancy was reduced by 
7–10 years overall in individuals with osteogenesis imper­
fecta, with approximately one­quarter of deaths occurring 
before 35 years of age7. Even severely affected patients 
reach an age at which other conditions that are not pri­
marily related to osteogenesis imperfecta become more 
prevalent, such as malignancies. Treatment of these dis­
eases in patients with severe osteogenesis imperfecta will 
be a challenge, requiring re­evaluation of standard thera­
peutic procedures. For example, very limited knowledge 
exists of the relative osteogenesis imperfecta­related and 
non­disease­related contributions to heart diseases, how 
to treat these patients222,223 and whether modern therapeu­
tic procedures are feasible224. The positive results reached 
in the paediatric field by treating patients in multidisci­
plinary teams should encourage all physicians to develop 
differentiated therapeutic strategies to also improve the 
situation for adults with osteogenesis imperfecta.
Emerging therapeutics
New pharmacological strategies are emerging that offer 
novel ways to address the fragility phenotype inherent to 
osteogenesis imperfecta. Increased TGFβ signalling has 
been observed in osteoblasts of patients225 and in mouse 
models of osteogenesis imperfecta31,226; it is not yet clear 
to what extent the detected increase is a bystander effect. 
TGFβ­neutralizing antibodies can improve trabecu­
lar bone mass, cortical thickness and bone strength in 
Crtap−/− mice through combined reductions in both 
osteoclast and osteoblast activity. In addition, inhibition 
of the TGFβ pathway improves lung ultrastructure in 
this model226. Similar trabecular results were observed 
in Col1a2+/p.G610C (Amish) mice, suggesting that exces­
sive TGFβ signalling might have a role in dominant and 
recessive models of osteogenesis imperfecta226.
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Anti­sclerostin therapy227 might have a role in 
osteo gene sis imperfecta management by promoting 
 osteo blast recruitment and activity (FIG. 4a), provided 
that osteoblasts with collagen or collagen­related defects 
prod uce sufficient bone mass to overcome matrix level 
deficiencies in bone quality. Anti­sclerostin treatment 
for 2 weeks in 8­week­old Brtl/+ mice led to increased 
bone formation compared with placebo treatment228. 
To understand the efficacy of this approach during periods 
of rapid growth, Brtl/+ mice were treated from 3 weeks of 
age for 5 weeks — a period in which Brtl/+ mice more 
than doubles their body mass229. Compared with vehi­
cle treatment, cortical thickness increased as a result of 
increased bone formation and reduced bone resorp­
tion229. Similar improvements in cortical and trabecu­
lar bone were observed in Col1a2+/p.G610C mice treated at 
6 weeks of age, and in recessive Crtap−/− mice treated 
at 1 week or 6 weeks of age230. The cortical bone gains in 
young Brtl/+, Col1a2+/p.G610C and Crtap−/− mice translated 
into significant improvements in pre­yield measures 
of bone strength and stiffness228–230. Although post­yield 
bone brittleness remained unchanged, Raman spectro­
scopic analyses of bone of age­matched controls suggest 
that anti­sclerostin treatment may alleviate the high 
mineral to matrix ratio in newly formed bone tissue.
However, osteogenesis imperfecta is highly hetero­
geneous, and the underlying severity may influence the 
response to anti­sclerostin therapy. Although 4­week­
old Col1a1Jrt/+ mice, carrying an exon 9 splice donor 
site defect in one allele, showed 60% increase in distal 
fem oral trabecular bone mass and nearly 20% increase 
in cortical thickness when treated for 4 weeks with a dis­
tinct, but similar, anti­sclerostin antibody as described 
above, the treatment did not translate to a structural 
benefit in the lumbar vertebrae or to a biomechani­
cal benefit in the long bone, and 5­month­old mice 
showed no structural or biomechanical benefit at these 
sites231. Importantly, anti­sclerostin treatment will prob­
ably require sequential anti­resorptive intervention to 
preserve trabecular gains following cessation of anabolic 
therapy, although at levels that are lower than those used 
for primary intervention232.
Molecular and cell therapy
Osteogenesis imperfecta is a genetic disease and its 
definitive cure will require the correction of the DNA 
defect. However, for classic osteogenesis imperfecta due 
to structural defects in COL1A1 and COL1A2 (BOX 1), 
specific suppression of the mutant COL1A1 or COL1A2 
allele would convert the severe phenotype, owing to the 
dominant negative structural defect in collagen, to the 
milder form associated with the presence of a reduced 
amount (about half of normal) of collagen with normal 
structure233. Gene therapy approaches, using various 
silencing techniques (that is, ribozymes, small interfer­
ing RNA and short hairpin RNA), have been attempted 
in vitro and await final proof of principle in vivo234. Cell 
therapy using normal transplanted multipotent cells has 
also been attempted in preclinical and clinical  trials, but 
cell engraftment was low235. Studies reported improved 
bone mechanics in mice receiving wild­type human 
fetal chorionic stem cells236. There remains a need to 
determine the best cell type and the optimum trans­
plant timing to obtain higher engraftment in the bone 
compartment237. A clinical trial is approved in Europe 
to investigate the safety and effect on bone metabolism 
of fetal mesenchymal stem cells to enhance the produc­
tion of normal collagen in children and fetuses with 
osteogenesis imperfecta. Cells will be given during the 
first months after birth or already in utero depending 
on the time of diagnosis (BOOSTB4; European Union 
Project ID: 681045)238.
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